NLSDays 2022 Super Sessions Highlights!

Grand Opening: Power-up through partnerships – How level playing fields create a push for growth
Hosted by SwedenBIO, Sponsored by Novo Nordisk – read more

Super Session #1 – Diving into Deep Tech – From Buzzword to Benefit in Life Science
Hosted by Finland, Sponsored by Boehringer Ingelheim – read more

Super Session #2 – Vertical Life Science – How Convergence is Erasing Silos
Hosted by Sweden, Sponsored by AstraZeneca – read more

Super Session #3 – Vaccine Crosslinks: From Cancer to Covid 
Hosted by Norway, Sponsored by EVERSANA & Pharma Intelligence – read more

Super Session #4 – A Multi-Omics Approach to Disease
Hosted by Iceland, Sponsored by MSD – read more

Super Session #5 – Gender Science: Reproducing for the Other 50% 
Hosted by Denmark, Sponsored by Ferring Pharmaceuticals – read more

Super Session #6 – Follow the Money – Investors Leading the Way to Sustainability
Hosted within the NLSInvest track, Sponsored by DNB and Business Sweden – read more

NLSInvest@NLSDays 2022!

January – August 2022 – NLSInvest Rising Stars application process – APPLICATIONS CLOSED!
Life science companies from the Nordics will have the opportunity to apply to join the NLSInvest Rising Stars challenge to be held during NLSDays 2022. The application form, qualifying criteria and selection criteria are available here.

Early September 2022 – NLSInvest Rising Stars final selection
Our Nordic committee (including Nordic incubators, accelerators, qualified investors, and support organizations) will select 40 applicants to join NLSDays – at no cost.

27 September: NLSInvest Private Dinner
Open by invitation only to qualified investors, this private dinner will be a unique opportunity for investors to talk about their challenges and aims for the Life Science sector and the Nordics, as well an opportunity to develop potential cooperation.

28-29 September 2022 – NLSInvest pitch contest
The 40 selected companies will attend NLSDays 2022 – at no cost – to pitch before our global investor community and NLSDays audience, as well as to access our unique partnering platform for face-to-face meetings with potential partners.

29 September – NLSInvest Rising Stars Awards – NLSDays closing ceremony
From the 40 selected companies, 12 will be selected as finalists. Through panel-judge selection, 3 winners will be selected as NLSInvest 2022 Rising Stars Awardees during the NLSDays Closing Ceremony, during which they will receive their Awards and Prizes.”

Face-to-face meetings

Partnering at NLSDays is powered by the BIO One-On-One Partnering™ system, the leading web-based life sciences partnering system.

  • Two days of onsite partnering meetings on 28-29 September 2022
  • Search for partners, customers or clients
  • Request meetings with selected companies
  • Accept or decline meeting requests from others
  • Get your personal meetings scheduled before the conference starts
Learn more

Super Sessions & Fireside Chats

Learn about the latest trends and success stories in therapeutic area-focused sessions on R&D, business development and investment and connect to key executives speaking at NLSDays. The program features high executive level keynote speakers and panelists who openly share their insights and opinions on many important life science issues.

View NLSDays 2019 Photos Album © Camille Sonally

Company Presentations

6mn/12mn presentations: These sessions provide a forum for innovative companies and academia to present topical information on their projects, technologies, partnering opportunities and strategy. Presenters will have the opportunity to showcase their know-how and projects  during 6mn/12mn company presentations.

If you’re interested in presenting at NLSDays, please book it while registering.

Company presentations can also be included in exhibition and/or sponsorship. Please let us know while booking your package.

Presenting Companies will be “tagged” within BIO One-on-One Partnering.

Read more

Latest news in cooperation with Nordic Life Science

Svante Pääbo awarded the Nobel Prize in Medicine

Read more

SynAct Pharma submits IND for US clinical trial

Read more